1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Earnings

Reckitt Raises Guidance Following Sharp Improvement In Cold & Flu Sales

 
• By Tom Gallen

A sharp improvement in cold and flu sales trends in the third quarter has prompted Reckitt to increase its sales guidance for the full year. However, the UK-based firm is warning that these trends remain unpredictable for the remainder of 2021.

Close-up Of Hand Over Shopping Cart Symbol Button On Keyboard
• Source: Shutterstock

Reckitt Benckiser Group has raised its guidance for 2021 after a “sharp improvement in cold and flu sales trends” helped to deliver a stronger than expected performance in the third quarter.

The UK-based health and hygiene specialist now expects like-for-like net sales growth for the year in the range of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 
• By Malcolm Spicer

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 
• By Malcolm Spicer

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Nestlé Health Science’s US VMS Recovery Stutters

 
• By Tom Gallen

US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.

US Q1 Consumer Health Earnings Preview: Concern Unavoidable For Impact From ‘T’ Word

 
• By Malcolm Spicer

Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”

More from Business

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

Nestlé Health Science’s US VMS Recovery Stutters

 
• By Tom Gallen

US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.

OLLY Argues Standard Of Support For Kids Chillax Claims Casts Chill Over Supplement Advertising

 
• By Malcolm Spicer

NAD and NARB track their decisions on support for ad claims with Federal Trade Commission policies, including the requirement of RCTs to support health claims for supplements, a standard the industry argues is required for drug claims and shouldn’t be applied for dietary ingredients.